{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:17:35Z","timestamp":1791145055301,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.mayocp.2011.11.001","type":"journal-article","created":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T12:30:57Z","timestamp":1326112257000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":235,"title":["One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience"],"prefix":"10.1016","volume":"87","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitina","family":"Jimma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy M.","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhee","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mayocp.2011.11.001_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2011.11.001_bib2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.mayocp.2011.11.001_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF01878089","article-title":"Zwei Falle von Leukamie mit eigenthumlichem Blut- resp. Knochenmarksbefund","volume":"78","author":"Heuck","year":"1879","journal-title":"Arch Pathol Anat Physiol Virchows"},{"key":"10.1016\/j.mayocp.2011.11.001_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2011.11.001_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/blood.V51.2.189.189","article-title":"Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis","volume":"51","author":"Jacobson","year":"1978","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.001_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.leu.2404946","article-title":"The history of myeloproliferative disorders: before and after Dameshek","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"7037","key":"10.1016\/j.mayocp.2011.11.001_bib7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.mayocp.2011.11.001_bib8","volume":"126","author":"Silverstein","year":"1975"},{"key":"10.1016\/j.mayocp.2011.11.001_bib9","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"issue":"6020","key":"10.1016\/j.mayocp.2011.11.001_bib10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.mayocp.2011.11.001_bib11","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198512053132301","article-title":"Evidence of a new chimeric bcr\/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome","volume":"313","author":"Stam","year":"1985","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.mayocp.2011.11.001_bib12","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4944","key":"10.1016\/j.mayocp.2011.11.001_bib13","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.mayocp.2011.11.001_bib14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/j.1460-2075.1990.tb08212.x","article-title":"bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice","volume":"9","author":"Elefanty","year":"1990","journal-title":"Embo J"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.001_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.mayocp.2011.11.001_bib16","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.mayocp.2011.11.001_bib17","article-title":"SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients","author":"Lasho","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.mayocp.2011.11.001_bib18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ajh.22069","article-title":"Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN","volume":"86","author":"Thoennissen","year":"2011","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.mayocp.2011.11.001_bib19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2011.82","article-title":"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.mayocp.2011.11.001_bib20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2011.11.001_bib21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.mayocp.2011.11.001_bib22","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2011.11.001_bib23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.mayocp.2011.11.001_bib24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2011.11.001_bib25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2011.11.001_bib26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.mayocp.2011.11.001_bib27","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2011.11.001_bib28","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.001_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","article-title":"JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.mayocp.2011.11.001_bib30","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.001_bib31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients","volume":"25","author":"Caramazza","year":"2011","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.mayocp.2011.11.001_bib32","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2011.11.001_bib33","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.001_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","article-title":"Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995","volume":"61","author":"Mesa","year":"1999","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.mayocp.2011.11.001_bib35","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMc1109555","article-title":"Long-term outcome of ruxolitinib therapy in myelofibrosis","volume":"365","author":"Tefferi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mayocp.2011.11.001_bib36","article-title":"Long-term outcome of pomalidomide therapy in myelofibrosis","author":"Begna","year":"2011","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.mayocp.2011.11.001_bib37","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis","volume":"27","author":"Tefferi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2011.11.001_bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/leu.2010.254","article-title":"A phase-2 trial of low-dose pomalidomide in myelofibrosis","volume":"25","author":"Begna","year":"2011","journal-title":"Leukemia"},{"issue":"11, suppl","key":"10.1016\/j.mayocp.2011.11.001_bib39","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/(SICI)1097-0142(19971201)80:11+<2191::AID-CNCR5>3.0.CO;2-L","article-title":"Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia","volume":"80","author":"Bloomfield","year":"1997","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.mayocp.2011.11.001_bib40","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.mayocp.2011.11.001_bib41","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2011-08-371096","article-title":"Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically-annotated patients","volume":"118","author":"Tefferi","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2011.11.001_bib42","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1182\/blood-2010-11-320002","article-title":"Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival","volume":"117","author":"Vaidya","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2011.11.001_bib43","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2011.11.001_bib44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0609.2009.01216.x","article-title":"Karyotype complements the International Prognostic Scoring System for primary myelofibrosis","volume":"82","author":"Hussein","year":"2009","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.mayocp.2011.11.001_bib45","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/cncr.22630","article-title":"Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution","volume":"109","author":"Tefferi","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.mayocp.2011.11.001_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1600-0609.2009.01373.x","article-title":"Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival","volume":"84","author":"Patnaik","year":"2010","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.mayocp.2011.11.001_bib47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ajh.21391","article-title":"Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis\u2014increased serum ferritin or transfusion load does not","volume":"84","author":"Tefferi","year":"2009","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.mayocp.2011.11.001_bib48","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2011.11.001_bib49","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","author":"Tefferi","year":"2011","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.mayocp.2011.11.001_bib50","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2011.11.001_bib51","article-title":"IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.mayocp.2011.11.001_bib52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ajh.21972","article-title":"Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis","volume":"86","author":"Pardanani","year":"2011","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.mayocp.2011.11.001_bib53","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/leu.2010.258","article-title":"Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype","volume":"25","author":"Patnaik","year":"2011","journal-title":"Leukemia"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:25:37Z","timestamp":1758417937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0025619611000139"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2011.11.001","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2011.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}